Compare Macy's Inc (M) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Macy's Inc vs Stryker Corporation — how do they compare? Macy's Inc trades at $22.72 (market cap $5.95B), while Stryker Corporation trades at $277.73 (market cap $106.24B). The key difference: Stryker Corporation is far larger — about 17.9× Macy's Inc's market cap, and Macy's Inc pays the higher dividend (3.36%). Which is the better fit depends on your goals — on Pluang, investors hold Macy's Inc for 58 Days and Stryker Corporation for 21 Days on average.
| M | SYK | |
|---|---|---|
Market Cap | $5.95B | $106.24B |
Volume | 6,030,644 | 2,982,001 |
Sector | Consumer Cyclical | Health |
52-Week High | $26.21 | $388.35 |
52-Week Low | $16.51 | $269.75 |
Typical Hold Time | 58 Days | 21 Days |
Enterprise Value | $9.75B | $117.70B |
Dividend Yield | 3.36% | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Macy's stock trades at $22.61, down 0.79% on the day, with strong technical momentum indicated by bullish moving averages. The company demonstrates improving fundamentals with three consecutive quarterly earnings beats and a 'Bold New Chapter' strategy driving digital transformation. Valuation metrics appear attractive with P/E of 8.35 and P/S of 0.27, while profitability shows recovery with ROE of 15.99% and net margin improvement to 3.29%.
The outlook remains cautiously optimistic with analyst consensus at $24.25 representing 7% upside potential. Key opportunities include digital growth initiatives and dividend sustainability, while risks involve retail sector headwinds and uneven quarterly performance. The stock offers value characteristics with turnaround potential, supported by improved cash flow generation and balance sheet strength.
Stryker (SYK) trades at $279.15, up 1.36% on the day, amid a mixed technical and fundamental backdrop. The stock shows bearish technical signals with key support at $268 and resistance at $284, while fundamentals remain solid with a 14.43% net income margin and strong analyst consensus of 71% buy ratings. Recent news highlights ongoing legal scrutiny over manufacturing issues, but the company maintains robust cash flow and earnings growth, with Q3 2026 results pending.
Outlook: SYK offers growth potential with a consensus price target of $368.11, supported by profitability and innovation, but faces near-term risks from legal investigations and technical weakness. Investors should weigh strong fundamentals against sentiment headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Macy's Inc
Founded in 1858 and based in New York City, Macy's operates 570 stores under the Macy's nameplate, 58 stores under the Bloomingdale's nameplate, and 160 freestanding Bluemercury specialty beauty stores (as of the end of fiscal-year 2021). Macy's also operates e-commerce sites and licenses two Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances comprised 59% of Macy's 2021 sales.
Read more on M →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
